You are here: Industry Insights > Mitsubishi Tanabe

News List

Post-Hoc Study Analysis Examines Early Intervention with Edaravone for ALS Survival americanpharmaceuticalreview
March 25, 2021
Mitsubishi Tanabe Pharma America announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous (IV) edaravone treatment on disease progression milestones and events among people with amyotrophic lateral sclerosis (ALS).
Mitsubishi Tanabe, Daiichi Sankyo tie alliance for ALS treatment agent biospectrumasia
September 18, 2019
Daiichi Sankyo has its own sales and marketing organization in Brazil, and is strengthening its presence in Central and South America as one of initiatives to increase regional value in line with the market characteristics in each region.
Mitsubishi Tanabe, Daiichi Sankyo tie alliance for ALS treatment agent biospectrumasia
September 17, 2019
Through cooperation in Brazil, Mitsubishi Tanabe Pharma and Daiichi Sankyo will aim to provide edaravone to more ALS patients as soon as possible.
Why Edaravone of Mitsubishi Tanabe is Excellent? PharmaSources/1℃
August 14, 2019
Edaravone of Mitsubishi Tanabe was approved for marketing in China on July 31, 2019, with the acceptance No.: JXHS1900047 and indication of amyotrophic lateral sclerosis (ALS).
Mitsubishi Tanabe Pharma America Announces Collaborative Study To Identify And Measure Biomarkers In People With ALS americanpharmaceuticalreview
December 10, 2018
Mitsubishi Tanabe Pharma America, Inc. will conduct a study to identify and measure specific biomarkers in people with amyotrophic lateral sclerosis (ALS).....
Mitsubishi Tanabe Pharma to buy Neuroderm for $1.1 B biospectrumasia
July 27, 2017
The acquisition is intended to help the Japanese drug maker achieve its U.S. sales target of 80 billion yen by FY2020.